Pilot Study of Pancreatic Cancer Screening
-
- STATUS
- Recruiting
-
- End date
- Jan 31, 2032
-
- participants needed
- 250
-
- sponsor
- University of California, San Francisco
Summary
This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This study may lead to a greater understanding of cancer and potentially, improvements in cancer screening and treatment.
Description
PRIMARY OBJECTIVE:
I. To determine the event rate of abnormal magnetic resonance imaging (MRI) findings in screened study participants.
SECONDARY OBJECTIVES:
I. To determine the rates of high-grade pancreatic neoplasia precursors (intraductal papillary mucinous neoplasm (IPMN)-high-grade dysplasia (HGD)) and pancreatic intraepithelial neoplasia-3 [PanIN-3]) and pancreatic ductal adenocarcinoma (PDAC) among all study participants.
II. To understand rates of procedures (biopsies and surgeries) among all study participants.
EXPLORATORY OBJECTIVES:
I. To create a biorepository of all participants through the collection of saliva, blood, and tissue, combined with imaging findings and robust clinical annotation of patient health behaviors in all study participants.
II. To explore knowledge, attitudes, and anxiety related to pancreatic cancer screening at annual intervals in all study participants.
OUTLINE: Participants are assigned to 1 of 2 groups.
GROUP I: Participants may opt to undergo MRI/ magnetic resonance cholangiopancreatography (MRCP) annually for 10 years or complete questionnaires over 10 minutes and undergo blood, saliva and tissue sample collection.
GROUP II: Participants undergo MRI/MRCP screening annually for 10 years.
Details
| Condition | Pancreatic Carcinoma |
|---|---|
| Treatment | magnetic resonance imaging, Questionnaires, biospecimen collection, Endoscopic Ultrasound, Magnetic Resonance Cholangiopancreatography |
| Clinical Study Identifier | NCT05058846 |
| Sponsor | University of California, San Francisco |
| Last Modified on | 29 April 2022 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer